Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape
Key players, such as AstraZeneca, AbbVie, Roche, Merk, Novartis, Pfizer, Takeda Pharmaceuticals, Johnson & Johnson, Sanofi, Xcovery, Jiangsu Alphamab Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, etc., are involved in developing drugs for Non-Small Cell Lung Cancer (NSCLC).
DelveInsight’s “Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight Report 2021,” lays out comprehensive insights about 10+ companies and pipeline drugs in the Non-Small-Cell Lung cancer competitive landscape.
The NSCLC Pipeline insights report offers a 360° view of the therapeutics landscape by:
- Development stage
- Product type
- Route of administration
- Molecule type
- Mechanism Of Action
The Non-Small Cell Lung Cancer pipeline report lays down the business opportunities, threats, future collaborations, strong competitors, and growth strategies.
Key highlights from our report:
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.
- The therapies under development focus on novel approaches to treat/improve Non-Small-Cell Lung cancer (NSCLC).
- Incyte Corporation, in collaboration with Zai Lab Limited, is investigating their drug candidate, INCMGA00012 (MGA012), which is a proprietary humanized monoclonal Antibody
- Janssen, a Johnson and Johnson Company, is currently investigating their lead product JNJ-61186372 (JNJ-6372) in Advanced NSCLC patients.
- Apart from these therapies, there are some other potential emerging therapies are also in development for NSCLC, which are in phase I and I/II and have the potential to impact the dynamics of the NSCLC therapeutics market such as LAG3 (i.e., Eftilagimod alpha (Immutep), BI754111 (Boehringer Ingelheim), LAG525 (Novartis)).
Request for Sample @Non-Small Cell Lung Cancer Pipeline Insights and Outlook
Non-Small Cell Lung Cancer is a form of cancer in which malignant (cancer) cells develop in lung tissues.
NSCLC is a common form of lung cancer that accounts for around 85% of all lung cancers. However, NSCLC metastasis to other organs slower than SCLC, and microscopically, SCLC is composed of much smaller cells. Adenocarcinomas, squamous cell carcinomas, giant cell carcinomas, and adenosquamous carcinomas are the most common forms of NSCLC. Adenosquamous carcinomas and sarcomatoid carcinomas are less common.
Non-Small Cell Lung Cancer pipeline analysis: Drug Profile
The NSCLC Pipeline appears quite vast and rich with over 100 pharmaceutical companies in dynamically advancing the NSCLC pipeline forward developing novel therapeutic agents in different clinical stages. The NSCLC pipeline report proffers a comprehensive analysis of key companies including Novartis Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals, AbbVie, Janssen Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Cstone Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck, Merck/Pfizer, Amgen, Mirati Therapeutics/Bristol-Myers Squibb, Beigene, Incyte Corporation, Xcovery, Daiichi Sankyo, Inc., Shanghai Henlius Biotech, Qilu Pharmaceutical and several others with their pipeline therapeutic agents.
1. Nazartinib/EGF816 by Novartis Pharmaceuticals
In patients with advanced EGFR-mutant NSCLC, it is a third-generation EGFR TKI that selectively targets activating (L858R, ex19del) and resistance (T790M) mutants while sparing wild-type EGFR. EGF816 covalently binds to mutant forms of EGFR, including the T790M EGFR mutant, and inhibits their activity after oral administration, preventing EGFR-mediated signalling.
2. Telisotuzumab Vedotin by AbbVie
It is an antibody-drug conjugate (ADC) targeting c-Met that is being investigated to treat NSCLC. Upon intravenous administration, the monoclonal antibody moiety of Telisotuzumab Vedotin targets and binds to c-Met expressed on tumour cells.
3. JNJ-61186372/JNJ-6372 by Janssen Pharmaceuticals
Janssen, a Johnson and Johnson Company, is currently investigating their lead product JNJ-61186372 (JNJ-6372) in Advanced NSCLC patients. It is a novel Human Bispecific EGFR and c-Met Antibody that the company believes can benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.
4. Canakinumab (ACZ885) by Novartis Pharmaceuticals
It is an injectable human monoclonal antibody intended to bind to human interleukin-1 beta (IL-1 beta). Its mode of action is based on the neutralization of 1β signalling, resulting in suppressing inflammation in patients with disorders of autoimmune origin.
Dive deeper to know more @ Non-Small Cell Lung Cancer therapeutics and drugs pipeline
Non-Small Cell Lung Cancer (NSCLC) Key Pharma Players Involved:
- Novartis Pharmaceuticals
- Jiangsu Alphamab Biopharmaceuticals
- AbbVie
- Janssen Pharmaceuticals
- Chia Tai Tianqing Pharmaceutical Group
- Cstone Pharmaceuticals
- Novartis Pharmaceuticals
- Takeda Pharmaceuticals
- Sanofi
- Merck
- Merck/Pfizer
- Amgen
- Mirati Therapeutics/Bristol-Myers Squibb/Beigene
- Incyte Corporation
- Xcovery
Non-Small Cell Lung Cancer (NSCLC) Therapies Involved:
- Nazartinib/EGF816
- KN046
- Telisotuzumab Vedotin
- TQB2450
- Sugemalimab/CS1001
- Canakinumab (ACZ885)
- Veliparib
- TAK-788
- SAR408701
- TEPMETKO (tepotinib)
- Avelumab
- AMG 510
- Sitravatinib (MGCD516)
- INCMGA00012/MGA012
- Ensartinib/X-396
Non-Small Cell Lung Cancer pipeline therapeutics assessment:
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Intravenous
- Inhalation
- Sub-cutaneous
- By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
- Targets:
- Protease
- Immunomodulatory
- Multiple Kinase Inhibitor
- By Mechanism of Action
- NMDA receptor modulators
- NMDA receptor agonists
- CYP2D6 inhibitor
- Serotonin 1A receptor agonists
- Trace amine-associated receptor one agonists
- Muscarinic M4 receptor modulators
Reach out for more information: NSCLC Drug Pipeline Assessment
Scope of the Report:
- Coverage: Global
- Key Market Players: Novartis Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals, AbbVie, Janssen Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Cestone Pharmaceuticals, Novartis Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck and others,
- Key Pipeline Therapies: Nazartinib, KN046, Telisotuzumab Vedotin, JNJ-61186372, TQB2450. TQ-B3139, TQB2450, Sugemalimab, Canakinumab, Veliparib, TAK-788, SAR408701, TEPMETKO and others.
Table of Contents:
| 1. | Report Introduction |
| 2. | Non-Small Cell Lung Cancer (NSCLC) |
| 3. | Non-Small Cell Lung Cancer (NSCLC) Current Treatment Patterns |
| 4. | Non-Small Cell Lung Cancer (NSCLC) – DelveInsight’s Analytical Perspective |
| 5. | Therapeutic Assessment |
| 6. | Non-Small Cell Lung Cancer (NSCLC) Late Stage Products (Phase-III) |
| 7. | Non-Small Cell Lung Cancer (NSCLC) Mid Stage Products (Phase-II) |
| 8. | Early Stage Non-Small Cell Lung Cancer (NSCLC) Products (Phase-I) |
| 9. | Non-Small Cell Lung Cancer (NSCLC) Pre-clinical Products and Discovery Stage Products |
| 10. | Inactive Products |
| 11. | Dormant Products |
| 12. | Non-Small Cell Lung Cancer (NSCLC) Discontinued Products |
| 13. | Non-Small Cell Lung Cancer (NSCLC) Product Profiles |
| 14. | Non-Small Cell Lung Cancer (NSCLC) Key Companies |
| 15. | Non-Small Cell Lung Cancer (NSCLC) Key Products |
| 16. | Dormant and Discontinued Products |
| 17. | Non-Small Cell Lung Cancer (NSCLC) Unmet Needs |
| 18. | Non-Small Cell Lung Cancer (NSCLC) Future Perspectives |
| 19. | Non-Small Cell Lung Cancer (NSCLC) Analyst Review |
| 20. | Appendix |
| 21. | Report Methodology |
Request for a Webex demo @ Non-Small Cell Lung Cancer Pipeline and get a walk-through of our report
Key questions answered:
- How many firms are working on treatments for Non-Small-Cell Lung Cancer (NSCLC)?
- How many Non-Small-Cell Lung Cancer (NSCLC) drugs does each company develop?
- How many emerging drugs for Non-Small-Cell Lung Cancer (NSCLC) treatment are in mid-stage and late-stage development?
- What are the most critical partnerships (industry–industry, industry-academia), mergers and acquisitions, and licencing activities related to NSCLC therapeutics?
- What are the latest developments, medication styles, and new technologies that have been created to address the limitations of current therapies?
- What are clinical trials being conducted for Non-Small-Cell Lung Cancer?
- What are the most significant partnerships (industry–industry, industry-academia), mergers and acquisitions, and licencing activities involving NSCLC therapeutics?
- What are the latest developments, medication styles, and new technologies that have been created to address the limitations of current therapies?
- What clinical trials are being conducted for Non-Small-Cell Lung Cancer (NSCLC), and how far along are they?
Read more about drugs and therapies in Non-small cell lung cancers Market @ Imfinzi Lung Cancer
Related reports:
Non-Small Cell Lung Cancer (NSCLC) Market
Get comprehensive historical and forecast analysis of Non-Small Cell Lung Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AstraZeneca, AbbVie, Roche, Merk, Novartis, Pfizer, Takeda Pharmaceuticals, Johnson & Johnson, Sanofi, Xcovery, Jiangsu Alphamab Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group and several others.
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) Pipeline
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Heat Biologics, Bristol-Myers Squibb, Merck, Amgen, Roche, Turning Point Therapeutics, Xcovery and several others.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer, Takeda, Xcovery Holding Company and several others.
BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer, Astellas Pharma, Seattle Genetics and several others.
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Merck, Novartis Pharmaceuticals and several others.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AstraZeneca, Takeda, Janssen, Yuhan Corporation and several others.
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AstraZeneca, Merck, Novartis Pharmaceutical, Bristol-Myers Squibb, Regeneron Pharmaceuticals and several others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
The post Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape appeared first on Financial Market Brief.
